Alzchem beats Q1 earnings despite sales miss on steel weakness By Investing.com

Alzchem’s Q1 results were mixed but slightly better than expected, with EPS of €1.77 beating the €1.65 consensus by 7% and EBITDA of €32.3 million topping estimates by 6%. Sales rose 2.7% to €148.7 million but missed consensus by 1%, pressured by a 0.6% volume decline and a 2.2% FX headwind amid weakness in Europe’s steel market. The company reaffirmed 2026 guidance for about €600 million in sales and €126 million in EBITDA, supported by ongoing capacity expansions in creatine and nitroguanidine.

Analysis

The key signal is not the modest headline beat; it is the widening divergence between the specialty growth engine and the legacy industrial exposure. When a company can still protect pricing in a growth niche while its cyclical segment deteriorates with European steel, it usually means the mix shift is becoming the main equity story — and that can support valuation expansion even if aggregate revenue looks pedestrian. The market should focus on the fact that incremental margin is coming from higher-value products, which lowers sensitivity to commodity cycles and makes the business less dependent on a clean macro recovery.

The bigger second-order effect is capacity discipline. Expanded creatine and nitroguanidine output into 2H26/2H27 creates a multi-quarter runway for volume-led earnings growth, but it also introduces execution risk: commissioning delays, startup inefficiencies, or a price response from competitors could compress the upside before the new assets fully monetize. In the near term, the weak cash conversion is a reminder that growth is being funded through working capital and capex rather than operating cash, so the stock can remain vulnerable if investors start to discount the 2026 guidance as too back-end loaded.

The contrarian angle is that the market may be underestimating how much this business benefits from scarcity in differentiated chemical intermediates. If specialty end-markets continue to outgrow the broader industrial cycle, the earnings profile can re-rate from a cyclical chemical name toward a higher-quality industrial compounder. The risk to that view is a sustained Europe downturn or FX drag that masks operating leverage for another 2-3 quarters, creating a better entry point only after momentum fades.

Key Decisions for Investors

• Long ACT1 on weakness over the next 1-2 weeks if the market sells the cash flow miss too aggressively; use a 6-12 month horizon and target a re-rating on the back of specialty mix expansion and 2026 guidance credibility.
• Pair trade: long ACT1 / short a Europe-facing basic materials or steel-linked chemical proxy for a 3-6 month relative-value expression; the spread should work if specialty pricing holds while cyclicals remain pressured.
• Avoid chasing after the print; wait for a pullback of 5-8% to improve entry, since the near-term catalyst path is mostly execution rather than immediate earnings inflection.
• For risk-managed upside, consider a call spread in ACT1 dated 6-9 months out to capture the expected rerating while limiting downside from commissioning delays and FX volatility.